Influenza: Reducing Complications in High-risk Patients Through Advanced Treatment Options

The 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting has been canceled in response to the COVID-19 pandemic.

Due to this cancellation, all ancillary events, including this event will no longer take place.

We would like to thank you for your understanding and invite you to check our organizer page for future CME activities related to this topic: http://vindicocme.eventbrite.com/. 

Activity Chair

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Overview

Although the impact of influenza varies, it places a substantial burden every year on the health of people in the United States. The Centers for Disease Control and Prevention estimates that influenza has caused between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. Most hospitalizations and deaths occur in patients who are at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions, such as asthma or chronic obstructive pulmonary disease. To better manage influenza in high-risk patient populations, clinicians must keep apprised of new information regarding the timely diagnosis and treatment of influenza as well as be equipped to compare the efficacy and safety of available antiviral therapies for prophylaxis and treatment. In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using case-based examples, experts will demonstrate approaches for selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Agenda

6:30 PM
Registration and Dinner

7:00 PM
Introduction and Pretest
Paul G. Auwaerter, MD, MBA, FIDSA

7:05 PM
Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

7:35 PM
Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

7:50 PM
Challenging Case 2: 13-Year-Old Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

8:05 PM
Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

8:20 PM
Posttest

8:25 PM
Question and Answer

8:30 PM
Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.

• Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.

• Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Target Audience

The intended audience for this activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

This program is not sponsored or programmed by the AAAAI.

This non-CME educational program is provided by Vindico Medical Education.

This activity is supported by an educational grant from Genentech, Inc.

This educational program has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

This live activity is not approved for AMA PRA Category 1 Credit(s)™.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.